Ann: Quarterly Activities Report and Appendix 4C, page-51

This is all very interesting Halo99. But what exactly does Exopharm contribute to LOAD and EVPS?

Up until January this year the business was promoting ‘Exclusive’ and ‘Proprietary’ LOAD and EVPS platforms.

“Exopharm also has two exclusive proprietary technologies that allow advanced customisation of exosomes – the LOAD technologies improve loading of active ingredients (e.g. DNA, RNA, small molecules and proteins) into exosomes and the EVPS technologies allow exosomes to be directed towards selected cell types.” 4C 31 January 2022.

Most recently these LOAD and EVPS are described as “ Exopharm’s exosome technologies solve important needs for the success of exosome medicines – LEAP manufacturing technology, LOAD API loading technologies and EVPS tropism technologies. “ 4C 29 April 2022.

Are these platforms still ‘proprietary’ and ‘exclusive’?

What has happened here?